| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2016-12-15 | Cyprotex (UK) | Evotec (Germany) | £ 55.36 m (€ 66.3 million) | CRO Technology - Services |
| 2016-12-15 | BioPhausia (Sweden) | Karo Pharma (Sweden) | SEK 908 million (€ 91.92 million) | |
| 2016-12-15 | TangenX Technology (USA - MA) | Repligen (USA - MA) | €37 million ($ 39 million) | Technology - Services |
| 2016-12-10 | Encore Vision (USA - TX) | Novartis (Switzerland) | undisclosed | Ophtalmological diseases |
| 2016-12-07 | Lonza's peptides business and operations in Brain-l'Alleud | PolyPeptide Laboratories (USA - CA) | undisclosed | Technology - Services |
| 2016-12-02 | Acetylon Pharmaceuticals (USA - MA) | Celgene (USA - NJ) | undisclosed | Cancer - Oncology Autoimmune diseases |
| 2016-11-30 | G7 Therapeutics (Switzerland) | Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) | CHF 12 million | Technology - Services |
| 2016-11-29 | Aegerion Pharmaceuticals (USA - MA) | QLT (Canada), now Novelion Therapeutics (Canada) | ||
| 2016-11-22 | Chase Pharmaceuticals (USA - MD) | Allergan (Ireland) | $125 million and additional milestone payments | |
| 2016-11-21 | Atopix Therapeutics (UK) | Chiesi Farmaceutici (Italy) | €75 million | Allergic diseases - Respiratory diseases |
| 2016-11-21 | Selexys Pharmaceuticals (USA - OK) | Novartis (Switzerland) | up to $665 million in upfront, acquisition and milestone payments | Hematological diseases - Rare diseases |
| 2016-11-08 | AccelLAB (Canada) | CiToxLAB (France) | undisclosed | Technology - Services - Medical devices |
| 2016-11-01 | Tobira Therapeutics (USA - CA) | Allergan (Ireland) | up to $1.695 billion | Hepatic diseases - Liver diseases |
| 2016-11-01 | Kolltan Pharmaceuticals (USA - CT) | Celldex Therapeutics (USA - NJ) | $ 235 million (€ 214.1 million) | Cancer - Oncology |
| 2016-10-31 | Telesta Therapeutics (Canada) | Prometic Life Sciences (Canada) | Cancer - Oncology Immunological diseases |
|
| 2016-10-28 | Ganymed Pharmaceuticals (Germany) | Astellas Pharma (Japan) | up to € 1.28 billion | Cancer - Oncology |
| 2016-10-27 | Rhythm Health, now Motus Therapeutics (USA - MA) | Actavis, now Allergan (Ireland) | $200 million and contingent payment upon first commercial sale of relamorelin | Gastrointestinal diseases |
| 2016-10-13 | animal health vaccines and pharmaceuticals from Merial portfolio | Ceva Santé Animale (France) | undisclosed | Veterinary medicine |
| 2016-10-12 | Immunetics (USA - MA) | Oxford Immunotec (UK) | up to $ 12 million | |
| 2016-10-07 | PharmaCore (USA - NC) | Cambrex (USA - NJ) | $25 million | Technology - Services |
